News | June 21, 2025
Biocon concludes a Rs 4,500 crore equity fundraise through QIP
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
25 women students to receive internship, training, and mentorship in Life Sciences segment
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Dhiraj brings 20+ years of extensive executive-level financial expertise across various industries including Pharma, Media, Retail, and FMCG
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated
